{"name":"2seventy bio","slug":"2seventy-bio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"bb21217","genericName":"bb21217","slug":"bb21217","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"bb21217","genericName":"bb21217","slug":"bb21217","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPaUZPN2pyQWJVcy1FTnB6b2RPeTJtbm1rY1BlUFBYbGZrZFhtUHFVcjFYOFlhUGI2cjFxcWVWMExKRlR0YV9SaHZ1XzdCOTgzNXZQZlotOG1Gdk8zWnB5Sy05cTJHTEM5OXJFMS03WWYyd2VQSEZrZWU1NEJNaUMwNXJMZEpQcXdSRnNzNzNoeGJMOTZxYndOU25naXNDWTdJaUQ1YkdLa0N6MVJRQnlIX3d1VQ?oc=5","date":"2025-10-24","type":"deal","source":"BioSpace","summary":"Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move - BioSpace","headline":"Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNM3BMT1FDRVZiaVJoZGx1cnNER3ZmV05vZVVGdk9UZ3VzMTNjZnd5QkpUYjhzQ1FPaFVjZkt5YzlfY1lNRW9sQk1VenZ1R1V5cUJmaGlWWlgxRHVXa2h2TDJrMlJVRE9RcklxQWtwWUtnYi1ZVjJHNVpzcVlSZWJKbFNEaUlNc0ZjQm0xZ2NuV05vcFJrR1IydE9RbTRYdEFaOENuLVJZblQ0UHkxaUlTSVhMYw?oc=5","date":"2025-10-23","type":"trial","source":"fiercebiotech.com","summary":"Regeneron does 180 on 2seventy lymphoma CAR-T, halting study and nixing further development - fiercebiotech.com","headline":"Regeneron does 180 on 2seventy lymphoma CAR-T, halting study and nixing further development","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOclJxMGh1dVFISEpLY25URDhNQ0ZISG5nNjZiVDFfRVdrN1BxR2V0VVVXWDJwZzAxa0loX1JCQThJR1Y5X09NZVI1X2hOdnhlQ3drMm5EbHdtYzNfa01GN19tY3hqaHQ3WVloa0xady1YcTl4X2QzYThWUmdyR1dkbjVpaXhadkU4OUM0YVloR3dWYmFYNkNqRXI1Uy1GWE41ZG85b1R0RWNpZWRGMHY0?oc=5","date":"2025-05-13","type":"deal","source":"Investing.com","summary":"2seventy bio completes merger with Bristol-Myers Squibb - Investing.com","headline":"2seventy bio completes merger with Bristol-Myers Squibb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNS1h1MzkzU25weGNnSC0zSnlHVmdlbGtPZllWZko5NDZYNmVCZUl2em1sbkFaQ0VYazB0SFFLUjgzU2RJZEpJQkJaYl9zY09QRlJBV3laWlRFdW5GOXZTcTJBcTlVejRqN2pjMTQ2aDA1UDM0a1ViNy1OQWhWZ0h4MnF5NW1obE5WblJSOHROVlRITFoySVE?oc=5","date":"2025-03-13","type":"deal","source":"Contract Pharma","summary":"Bristol Myers Squibb to Acquire 2seventy bio - Contract Pharma","headline":"Bristol Myers Squibb to Acquire 2seventy bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTjNWWVNaWkk4WXNrQzNIdnV1ZWNlWTYzR1M3T2NwYl9NMDJjS2F1ZW96TzhfcG9jX28wbG5lV3NzUVQyVHAyVklaZXVZQXdfb2c3eDVjT1pqT3Vhb1hqZVlraWpaTTM2NlV4NTVNS2ctcUNpdVJIa0M2bDc0S2dOaFE5NVgyTDFLUUhuSFM2ZVNLeU90?oc=5","date":"2025-03-11","type":"pipeline","source":"BioPharma Dive","summary":"2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive","headline":"2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNRHRucl82Mk5XcUtNbmJrVURlaVM2NmpaeVZmVnA2dXl6RURYQjl3VjBXdkFha18yVG5WdXZzQ0hJZGMwUVZxT1JLVFEyRTZMSkVDYXhYQlpRcHdYWVk4VE9UMU5ibnZ4Q2N0OWdIVzN6ZjNkN29qSWRGMW5icmxUQ1gxZnd3NE9BSngtZWxGQ3BUUU1vbnI2ZDE2QmxMelA1dDZHNmtvbW4zNzdQUlVseEp1NHY?oc=5","date":"2025-03-11","type":"deal","source":"Pharmaceutical Technology","summary":"BMS to acquire longtime cell therapy partner 2seventy bio for $286m - Pharmaceutical Technology","headline":"BMS to acquire longtime cell therapy partner 2seventy bio for $286m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPNHBsMFgtTG5vUnNKUmNLeUwyT3BJckhIUWM4cDNMQm9yWUtMM2VSYmF4NjdaejRRSTY0X0RtVlQ1VlhVN2NtcW5KRld0a0UzellHdzNiSW5HRzVoUmJmTUViSEQzc3RPZVpNSDJlY21oVGFmaFFHaEtfUDkzUHN2aFBPbFRycVZ6UnROWTVmSUM1RFJGaXhNWXdVMy1CZFg5UVl2bURvY0lmekU?oc=5","date":"2025-03-11","type":"deal","source":"MedCity News","summary":"Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal - MedCity News","headline":"Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNc1VMVjVmQlNTbUdndnF3XzlkS3FaVGJlclFVYkw5WDN1bnBsMnhEcEt3d1ozN2QxbDNSQTBtV0FxNWpnODhoVkxfS2E4S2tsOHZqWGlGM3VXcUVsSG94NzBGc1EwMmdxcVVKX0RpWlMwWnZPeEx0UmJCQmdjNVYyWXVzUFU4MUlqaC1DbkRRTlBicXJlUmI2d0kzQ1pTbnJyV0tOaVNweVEzZTlFQ3p0REZNSVpmTXB6M0NGTkxHMmhLdGl4RnZ1WF9FS0NCdXhRbktkQ3lhOGRsUklGTVpR?oc=5","date":"2025-03-11","type":"deal","source":"Reuters","summary":"Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters","headline":"Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1mYU5SMHZTSzIySFY5NktJc3BqazZCdjdyZ1RfWTczX3NjMk9zcmRPNGdqamFHOXpyNnlVOFpBUkFHVVJTVUtIVnlGLWNOQ3F2NExRY042Z2hXNXhETXVHd2FjYmxvT3dFa2ZNWDQzV09zcGdab0VyMWVtamF3QQ?oc=5","date":"2025-03-11","type":"deal","source":"pharmaphorum","summary":"BMS absorbs CAR-T partner 2seventy bio for $286m - pharmaphorum","headline":"BMS absorbs CAR-T partner 2seventy bio for $286m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ON19jaHBjQXRTM3h6Y2JIb3Y4bjM4VDZwZk5FZHludnFMMGFNdGhpZVktVU9DUWpyVkhjUmZ6X0dLNTVlY2loZVd1aXZ5V09TRG9R?oc=5","date":"2025-03-11","type":"deal","source":"FirstWord Pharma","summary":"BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal - FirstWord Pharma","headline":"BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPS3V2MkZfWUE4ellncVpxTmEzMFlqOFpQU2tpS3c5UThXeV8yUFFxeGxZTUM5ZnN5QWw3eW9WU08zOUNMeXNTZTRkT1Z2UExOZWhxMlJoUTc4b0l0MnY1QXJoaENWdWZ0RHF6cHlhMi04eGxNci15TUVqWkJ5YUh3QXh1SUh3dS1BMjdPTTU5OW1DSk44?oc=5","date":"2024-06-27","type":"pipeline","source":"BioPharma Dive","summary":"2seventy slims down with sale of hemophilia assets to Novo - BioPharma Dive","headline":"2seventy slims down with sale of hemophilia assets to Novo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQNE1JQjZkS1BNVEtWZThuTFNmaUNULUhjdjdxY0tnWk16ZzBHT2UxZ1VyVzBxMW1paUFFMnhqSm1PaTFPdlRBM21jNk9sTHJJTllpeFlQNllZTlZfMXh5LVFOckJ1ZWxXS2ZSSW5tS0VGMm5CbUxSeHdSM3VieHV3NDFPTE5WTDFrYkFLZjYxWU90TkZaVjlWOHZJbmZWNTFjaW1pUlBuakdONnlMM2tRNQ?oc=5","date":"2024-01-30","type":"deal","source":"Fierce Pharma","summary":"Amid strategic pivot, 2seventy bio plots comeback for BMS-partnered CAR-T Abecma - Fierce Pharma","headline":"Amid strategic pivot, 2seventy bio plots comeback for BMS-partnered CAR-T Abecma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}